The disclosure provides skin probiotics, fermented media extract and fermentation byproducts thereof for the treatment of skin disease and disorders as well as for the prevention/treatment of acne and MRSA.

The disclosure provides skin probiotics, fermented media extract and fermentation byproducts thereof for the treatment of skin disease and disorders as well as for the prevention/treatment of acne and MRSA.

The disclosure provides topical pharmaceutical compositions comprising a macrolide immunosuppressant, e.g., selected from pimecrolimus, sirolimus, and tacrolimus, optionally in combination with efinaconazole, as well as the use of such compositions to treat inflammatory skin conditions.

The disclosure provides topical pharmaceutical compositions comprising a macrolide immunosuppressant, e.g., selected from pimecrolimus, sirolimus, and tacrolimus, optionally in combination with efinaconazole, as well as the use of such compositions to treat inflammatory skin conditions.

Compositions and methods for treating macrophage activation syndrome are provided.

Compositions and methods for treating macrophage activation syndrome are provided.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

The present invention is in the field of emulsifiers and provides novel emulsifier mixtures for use in cosmetic or pharmaceutical formulations or in detergents. The emulsifier mixtures according to the invention comprise a citrate ester mixture and at least one 1,2-alkanediol, 1,3-alkanediol, 1,4-alkanediol and/or 1,5-alkanediol and are characterized by increased stability and low precipitation over a wide temperature range and during a long storage period.

The present invention is in the field of emulsifiers and provides novel emulsifier mixtures for use in cosmetic or pharmaceutical formulations or in detergents. The emulsifier mixtures according to the invention comprise a citrate ester mixture and at least one 1,2-alkanediol, 1,3-alkanediol, 1,4-alkanediol and/or 1,5-alkanediol and are characterized by increased stability and low precipitation over a wide temperature range and during a long storage period.